Lothstein L - Search Results

1

Interaction of the novel anthracycline antitumor agent N-benzyladriamycin-14-valerate with the C1-regulatory domain of protein kinase C: structural requirements, isoform specificity, and correlation with drug cytotoxicity.

Roaten JB, Kazanietz MG, Caloca MJ, Bertics PJ, Lothstein L, Parrill AL, Israel M, Sweatman TW. Roaten JB, et al. Among authors: lothstein l. Mol Cancer Ther. 2002 May;1(7):483-92. Mol Cancer Ther. 2002. PMID: 12479266

2

Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis.

Barrett CM, Lewis FL, Roaten JB, Sweatman TW, Israel M, Cleveland JL, Lothstein L. Barrett CM, et al. Among authors: lothstein l. Mol Cancer Ther. 2002 May;1(7):469-81. Mol Cancer Ther. 2002. PMID: 12479265

3

Circumvention of nuclear factor kappaB-induced chemoresistance by cytoplasmic-targeted anthracyclines.

Bilyeu JD, Panta GR, Cavin LG, Barrett CM, Turner EJ, Sweatman TW, Israel M, Lothstein L, Arsura M. Bilyeu JD, et al. Among authors: lothstein l. Mol Pharmacol. 2004 Apr;65(4):1038-47. doi: 10.1124/mol.65.4.1038. Mol Pharmacol. 2004. PMID: 15044634

4

N-benzyladriamycin-14-valerate (AD 198) activates protein kinase C-delta holoenzyme to trigger mitochondrial depolarization and cytochrome c release independently of permeability transition pore opening and Ca2+ influx.

Lothstein L, Savranskaya L, Barrett CM, Israel M, Sweatman TW. Lothstein L, et al. Anticancer Drugs. 2006 Jun;17(5):495-502. doi: 10.1097/00001813-200606000-00002. Anticancer Drugs. 2006. PMID: 16702805

5

N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.

Lothstein L, Savranskaya L, Sweatman TW. Lothstein L, et al. Leuk Res. 2007 Aug;31(8):1085-95. doi: 10.1016/j.leukres.2006.11.003. Epub 2006 Dec 21. Leuk Res. 2007. PMID: 17187856

6

N-Benzyladriamycin-14-valerate (AD 198): a non-cardiotoxic anthracycline that is cardioprotective through PKC-epsilon activation.

Hofmann PA, Israel M, Koseki Y, Laskin J, Gray J, Janik A, Sweatman TW, Lothstein L. Hofmann PA, et al. Among authors: lothstein l. J Pharmacol Exp Ther. 2007 Nov;323(2):658-64. doi: 10.1124/jpet.107.126110. Epub 2007 Aug 10. J Pharmacol Exp Ther. 2007. PMID: 17693586

7

Resistance to N-benzyladriamycin-14-valerate in mouse J774.2 cells: P-glycoprotein expression without reduced N-benzyladriamycin-14-valerate accumulation.

Lothstein L, Sweatman TW, Dockter ME, Israel M. Lothstein L, et al. Cancer Res. 1992 Jun 15;52(12):3409-17. Cancer Res. 1992. PMID: 1350753

8

N-benzyladriamycin-14-valerate and drug resistance: correlation of anthracycline structural modification with intracellular accumulation and distribution in multidrug resistant cells.

Lothstein L, Wright HM, Sweatman TW, Israel M. Lothstein L, et al. Oncol Res. 1992;4(8-9):341-7. Oncol Res. 1992. PMID: 1362503

9

P-glycoprotein overexpression in mouse cells does not correlate with resistance to N-benzyladriamycin-14-valerate (AD 198).

Lothstein L, Koseki Y, Sweatman TW. Lothstein L, et al. Anticancer Drugs. 1994 Dec;5(6):623-33. doi: 10.1097/00001813-199412000-00003. Anticancer Drugs. 1994. PMID: 7888699

10

Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length.

Lothstein L, Rodrigues PJ, Sweatman TW, Israel M. Lothstein L, et al. Anticancer Drugs. 1998 Jan;9(1):58-66. doi: 10.1097/00001813-199801000-00007. Anticancer Drugs. 1998. PMID: 9491793

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters